Baxter International Inc. (NYSE: BAX) reported its fourth-quarter 2024 earnings, revealing sales from continuing operations of $2.75 billion, which represents a 1% increase on a reported basis and a 2% increase on a constant currency basis. This performance exceeded the company’s previously issued guidance. The adjusted earnings per share (EPS) for the quarter was $0.77, surpassing the consensus estimate of $0.52. The company's strong performance in its Pharmaceuticals and Medical Products & Therapies segments contributed to these results, although the impact of Hurricane Helene partially offset gains. Following the announcement, Baxter's stock rose by 7.5% in pre-market trading.